

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7208128

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JASON J. MARINEAU	02/28/2022
CLAUDIO EDMUNDO CHUAQUI	02/28/2022
STEPHANE CIBLAT	02/27/2022
ANZHELIKA KABRO	02/25/2022
HENRI PIRAS	02/28/2022
KENNETH MATTHEW WHITMORE	03/01/2022
KATE-LYN LUND	02/28/2022
RECEIVING PARTY DATA	
Name:	SYROS PHARMACEUTICALS, INC.
Street Address:	35 CAMBRIDGEPARK DRIVE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02140
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16962808
CORRESPONDENCE DATA	
Fax Number:	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 570-8764
Email:	us-patentbos@goodwinlaw.com, ddenhart@goodwinlaw.com, scannon@goodwinlaw.com
Correspondent Name:	GOODWIN PROCTER LLP
Address Line 1:	100 NORTHERN AVENUE
Address Line 2:	IP DOCKETING DEPT./7TH FL
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	SYR-035
NAME OF SUBMITTER:	DEREK DENHART
SIGNATURE:	/Derek Denhart/

DATE SIGNED:	03/04/2022
---------------------	------------

Total Attachments: 3

source=SYR_035_Executed_assignmentx#page1.tif

source=SYR_035_Executed_assignmentx#page2.tif

source=SYR_035_Executed_assignmentx#page3.tif

ASSIGNMENT BY INVENTORS

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I, Jason J. Marineau of 2 Mackintosh Street, Franklin, MA 02038 (USA); I, Claudio Edmundo Chuagui, of 83 Menotomy Road, Arlington, MA 02476 (USA); I, Stephane Ciblat of 1260, rue Pauline-Julien H2J 0A2, Montreal, QC (Canada); I, Anzhelika Kabro of 815, 49th Avenue H8T 2T3, Lachine, QC (Canada); I, Henri Piras of 21 Impasse le Hameau de la Colline 34990 Juvignac (France); I, Kenneth Matthew Whitmore of 300, Rue Mer Lafleche J4B 1C6, Boucherville, QC (Canada); and I, Kate-Lyn Lund of 765 Woodland Drive Oro-medonte, ON L3V 0R8 (Canada); (each an "Assignor" and collectively the "Assignors"), have made an invention described in the non-provisional patent application entitled "Inhibitors of Cyclin Dependent Kinase 7 (CDK7)" (the "Invention(s)"), which was filed on July 16, 2020, with the United States Patent and Trademark Office and assigned Application No. 16/962,808 ("the Patent Application"), which claims priority from International Application No. PCT/US19/13845, filed January 16, 2019 and U.S. Provisional Patent Application No. 62/617,884, filed January 16, 2018 (the "Patent Applications"), and I have sold, assigned and transferred by an agreement duly entered into and by these presents do hereby sell, assign and transfer my entire right, title and interest throughout the world in and to the Invention(s) and the Patent Applications to Syros Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 35 CambridgePark Drive, Cambridge, Massachusetts 02140 (USA) (herein "Assignee"), its successors and assigns ("Assignment").

This Assignment encompasses the Invention(s) and the Patent Applications as well as any patent application that claims the benefit of the priority date of the Patent Application under United States law or international convention and the invention(s) described therein, such applications including, but not limited to, any application entering the national phase from International Application No. PCT/US19/13845, any utility application or continuation thereof, including any continuation-in-part or divisional application, any patent application or patent issuing thereon subjected to a reinstatement, renewal, reissue or reexamination process, any patent application or patent issued thereon deemed an extension or substitution of the Patent Application or any of the foregoing applications, and any patent, including any Letters Patent, that issues from any of the foregoing applications or claims or has the right to claim priority thereto. This Assignment conveys to Assignee, its successors and assigns, the full right to claim all benefits and priority rights under any applicable law, convention, or treaty, including the right to sue for injunctive relief or damages caused by past infringement or any other cause of action accruing prior to this Assignment. The invention(s), Patent Applications and patent(s) referenced herein are to be held and enjoyed by the Assignee for its own use and behalf and for its successors and assigns until the full end of the term(s) for which any patent(s) may be granted as fully and entirely as if the same would have been held by me had this Assignment not been made.

I hereby acknowledge that this Assignment carries with it the right by Assignee to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of Assignee's selection and the right to procure the grant of all Letters Patent to Assignee in its own name. I hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue Letters Patent as described herein upon the Patent Applications or any application(s) based thereon, to the Assignee, its successors, or assigns.

I hereby agree, when requested, and without further consideration, to execute all oaths, assignments, powers of attorney, declarations, and any other papers necessary or desirable to fully secure to the Assignee the rights, titles and interests conveyed by this Assignment and to fully communicate to the Assignee all known facts relating to the Invention(s). I further agree to assist the Assignee by providing statements or testimony in any proceeding in which the Invention(s) may be involved, for consideration to be negotiated as need be and in good faith.


I represent that I have not made and will not make any assignment, grant, mortgage, license or other agreement that conflicts with the terms and covenants of this Assignment.

The terms and covenants of this Assignment shall inure to the benefit of the Assignee, its successor or assigns and shall be binding upon the Assignors and their respective heirs, legal representatives and assigns.

This Assignment is to be considered effective as of January 16, 2018.


IN WITNESS WHEREOF, the Assignors have executed this Assignment.

Assignors

DocuSigned by:

DB475F8790C3473

Jason J. Marineau

Date: 2/28/2022

DocuSigned by:

32E22EAE11BB431

Claudio Edmundo Chuaqui

Date: 2/28/2022

DocuSigned by:

0104780A058947C

Stephane Ciblat


Date: 2/27/2022

DocuSigned by:

9A0FCEB579A8489


Anzhelika Kabro

Date: 2/25/2022

DocuSigned by:

F2728818109DA98...

Date: 2/28/2022

Henri Piras

DocuSigned by:

B31A21521DD4A81

Date: 3/1/2022

Kenneth Matthew Whitmore

DocuSigned by:

481B48A7083D4FC...

Date: 2/28/2022

Kate-Lyn Lund

Accepted by Assignee's Authorized Representative:

Signature: 
087B1D65A5DD446

Representative's
Name: **Lee Crews**

Representative's
Title: **Assistant General Counsel, Intellectual Property**

Date: 3/1/2022